18 points) Prepare a statement of cash flows for ExoPharma Corp for the year ending December 31, 2019. See template on next page. ExoPharma's 2019 income statement revealed sales of $1,480,000; EBITDA margin of 16%; nterest expense of $26,000; and an effective tax rate of 27%. 2019 2018 (All Amounts in 000s) Assets Cash Accounts receivable Inventories Prepaids Land Building and equipment Less: Accumulated depreciation Total assets ExoPharma Corp Statement of Cash Flows For the year ending December 31, 2019 Cash flows from operating activities: Net income Add (deduct) noncash effects on operating income Depreciation expense Change in accounts receivable Change in inventory Change in prepaid insurance Change in accounts payable Change in accrued liabilities Change in income taxes payable Net cash provided by operating activities xox 180,000 238,000 14,000 250,000 1,500,000 (205,000) xox $ 466,000 70,000 280,000 xxx 250,000 1,300,000 (175,000 $ 2,208,300 THE FORELDRARDI $ Xxx 11,000 26,000 92,000 15,000 Liabilities Accounts payable Accrued liabilities Income taxes payable Stockholders' equity Common stock Paid in capital in excess of par Retained earnings Total liabilities and equity 810,000 990,000 632,000 $ 2,600,000 700,000 800,000 585,350 XXX Cash flows from investing activities: Purchase of equipment Net cash used by investing activities Cash flows from financing activities: Proceeds from issuing stock Dividends on common Net cash provided by financing activities Net change in cash Cash balance at January 1, 2019 Cash balance at December 31, 2019 18 points) Prepare a statement of cash flows for ExoPharma Corp for the year ending December 31, 2019. See template on next page. ExoPharma's 2019 income statement revealed sales of $1,480,000; EBITDA margin of 16%; nterest expense of $26,000; and an effective tax rate of 27%. 2019 2018 (All Amounts in 000s) Assets Cash Accounts receivable Inventories Prepaids Land Building and equipment Less: Accumulated depreciation Total assets ExoPharma Corp Statement of Cash Flows For the year ending December 31, 2019 Cash flows from operating activities: Net income Add (deduct) noncash effects on operating income Depreciation expense Change in accounts receivable Change in inventory Change in prepaid insurance Change in accounts payable Change in accrued liabilities Change in income taxes payable Net cash provided by operating activities xox 180,000 238,000 14,000 250,000 1,500,000 (205,000) xox $ 466,000 70,000 280,000 xxx 250,000 1,300,000 (175,000 $ 2,208,300 THE FORELDRARDI $ Xxx 11,000 26,000 92,000 15,000 Liabilities Accounts payable Accrued liabilities Income taxes payable Stockholders' equity Common stock Paid in capital in excess of par Retained earnings Total liabilities and equity 810,000 990,000 632,000 $ 2,600,000 700,000 800,000 585,350 XXX Cash flows from investing activities: Purchase of equipment Net cash used by investing activities Cash flows from financing activities: Proceeds from issuing stock Dividends on common Net cash provided by financing activities Net change in cash Cash balance at January 1, 2019 Cash balance at December 31, 2019